The United States Food and Drug Administration (FDA) has approved a groundbreaking new treatment option for adults diagnosed with acute myeloid leukemia, commonly known as AML. The newly approved therapy combines INQOVI, a fixed-dose oral treatment containing decitabine and cedazuridine, with venetoclax. This marks the first fully oral combination regimen approved for AML patients who are unable to undergo intensive induction chemotherapy.
The approval was announced by Taiho Oncology and Taiho Pharmaceutical on May 13, 2026. The decision could significantly improve treatment convenience and accessibility for older AML patients and those with serious health conditions that prevent aggressive chemotherapy treatment.
Acute myeloid leukemia is a fast-growing cancer that affects the blood and bone marrow. According to estimates, more than 22,000 people in the United States are expected to be diagnosed with AML in 2026. Many of these patients are elderly or have other medical conditions that make standard intensive chemotherapy too risky.
Traditionally, patients ineligible for intensive chemotherapy have relied on injectable hypomethylating agents combined with venetoclax. These therapies often require repeated hospital or infusion center visits. The newly approved INQOVI and venetoclax combination offers a fully oral alternative, potentially reducing the burden of frequent clinic appointments.
The FDA approval specifically applies to adults aged 75 years or older, as well as younger adults with health conditions that make intensive induction chemotherapy unsuitable.
The FDA based its approval on results from the Phase 2 ASCERTAIN-V clinical trial. The study evaluated the effectiveness and safety of INQOVI plus venetoclax in adults with newly diagnosed AML who could not receive intensive induction chemotherapy.
Researchers measured complete remission rates and duration of complete remission among participants. In the study:
Importantly, researchers reported no new safety concerns during the study. The findings suggest that the oral combination can provide meaningful clinical benefits while maintaining a manageable safety profile.
INQOVI is an oral fixed-dose combination of decitabine and cedazuridine. Decitabine is a DNA hypomethylating agent that works by helping restore normal function in bone marrow cells. Cedazuridine helps protect decitabine from being broken down too quickly in the body, allowing the medication to be effectively administered by mouth.
Venetoclax is a targeted therapy that blocks a protein called BCL-2, which helps cancer cells survive. By inhibiting this protein, venetoclax promotes cancer cell death.
Together, the combination is designed to attack leukemia cells while offering a more convenient treatment method compared with traditional injectable therapies.
Company leaders described the approval as an important advancement in AML treatment.
Peter Melnyk, President and Chief Executive Officer of Taiho Oncology, said the approval represents a significant milestone for AML patients who are not candidates for intensive chemotherapy. He emphasized the importance of providing a fully oral treatment option that supports patient-centered cancer care.
Harold Keer, MD, PhD, Chief Medical Officer of Taiho Oncology, also highlighted the potential benefits of reducing the treatment burden associated with hospital and infusion center visits. According to the company, expanding oral treatment options may improve convenience for both patients and caregivers.
Before this AML approval, INQOVI had already been approved in the United States and Canada for the treatment of myelodysplastic syndromes, often called MDS, and chronic myelomonocytic leukemia, known as CMML.
These conditions are disorders affecting bone marrow and blood cell production. The expanded approval further strengthens INQOVI’s role in treating hematologic malignancies.
Like many cancer treatments, INQOVI combined with venetoclax carries important safety warnings. One of the most significant risks is myelosuppression, a condition where bone marrow activity decreases, leading to low blood cell counts.
Potential complications may include:
Healthcare providers are advised to closely monitor blood counts before and during treatment. Some patients may require dose adjustments, treatment delays, growth factor support, or anti-infective medications.
The prescribing information also warns about embryo fetal toxicity. Women of reproductive potential should use effective contraception during treatment and for six months after the last dose. Male patients with female partners of reproductive potential should also use contraception during and after treatment.
Patients with moderate renal impairment may require closer monitoring because of the increased risk of adverse reactions.
The approval of an all oral AML treatment represents an important shift in cancer care delivery. Oral regimens can reduce travel demands, lessen time spent in medical facilities, and improve treatment flexibility for patients facing serious illness.
For older adults and medically vulnerable patients, reducing the physical and logistical burden of therapy can make a meaningful difference in quality of life.
As cancer treatment continues moving toward targeted and patient-friendly therapies, the INQOVI and venetoclax combination could pave the way for future oral treatment developments in blood cancers.
The AML treatment landscape has evolved rapidly in recent years, with increasing focus on personalized medicine, targeted therapies, and lower intensity treatment approaches for older adults.
The approval of INQOVI plus venetoclax highlights growing interest in oral oncology regimens that can maintain effectiveness while improving patient convenience. Researchers and clinicians will continue monitoring long-term outcomes and real-world patient experiences as the therapy becomes more widely used.
For many AML patients who cannot tolerate aggressive chemotherapy, this new treatment option may offer hope for improved disease management with fewer disruptions to daily life.
Taiho Oncology Official Announcement
This article is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Patients should consult qualified healthcare professionals regarding any medical condition or treatment decisions. Information in this article is based on company announcements and publicly available data at the time of publication.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.